Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
TEL AVIV, Israel, March 07, 2016 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will announce financial results for the fourth quarter and fiscal year ended December 31, 2015 and host a conference call and live audio webcast on Tuesday, March 29, at 8:30 a.m. Eastern Time.
| Tuesday, March 29, 2016 @ 8:30am Eastern Time | |
| Domestic: | 888-428-9480 |
| International: | 719-457-2648 |
| Conference ID: | 3465224 |
| Webcast: | http://edge.media-server.com/m/p/a4mzgp3s |
| Replays, available through April 6, 2016 | |
| Toll Free: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 3465224 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has demonstrated safety in >170 cancer patients and efficacy signals in an `all comers` Ph1 trial as well as in three tumor-specific Ph2 studies. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Ph3 pivotal trial for Recurrent Glioblastoma (rGBM); the trial is being conducted under an FDA Special Protocol Assessment (SPA), fast track and Orphan designation.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
